Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
Ghisoni E, Wicky A, Bouchaab H, Imbimbo M, Delyon J, Gautron Moura B, Gérard CL, Latifyan S, Özdemir BC, Caikovski M, Pradervand S, Tavazzi E, Gatta R, Marandino L, Valabrega G, Aglietta M, Obeid M, Homicsko K, Mederos Alfonso NN, Zimmermann S, Coukos G, Peters S, Cuendet MA, Di Maio M, Michielin O. Ghisoni E, et al. Among authors: pradervand s. Eur J Cancer. 2021 May;149:153-164. doi: 10.1016/j.ejca.2021.03.010. Epub 2021 Apr 14. Eur J Cancer. 2021. PMID: 33865201 Free article.
Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.
Romano E, Pradervand S, Paillusson A, Weber J, Harshman K, Muehlethaler K, Speiser D, Peters S, Rimoldi D, Michielin O. Romano E, et al. Among authors: pradervand s. Clin Cancer Res. 2013 Oct 15;19(20):5749-57. doi: 10.1158/1078-0432.CCR-13-0661. Epub 2013 Aug 15. Clin Cancer Res. 2013. PMID: 23948972
SPHN/PHRT - MedCo in Action: Empowering the Swiss Molecular Tumor Board with Privacy-Preserving and Real-Time Patient Discovery.
Raisaro JL, Troncoso-Pastoriza JR, Pradervand S, Cuendet M, Misbach M, Sa J, Marino F, Freundler N, Rosat N, Cavin D, Leichtle A, Fellay J, Michielin O, Hubaux JP. Raisaro JL, et al. Among authors: pradervand s. Stud Health Technol Inform. 2020 Jun 16;270:1161-1162. doi: 10.3233/SHTI200345. Stud Health Technol Inform. 2020. PMID: 32570563 Free article.
COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE).
Castelo-Branco L, Tsourti Z, Gennatas S, Rogado J, Sekacheva M, Viñal D, Lee R, Croitoru A, Vitorino M, Khallaf S, Šušnjar S, Soewoto W, Cardeña A, Djerouni M, Rossi M, Alonso-Gordoa T, Ngelangel C, Whisenant JG, Choueiri TK, Dimopoulou G, Pradervand S, Arnold D, Harrington K, Michielin O, Dafni U, Pentheroudakis G, Peters S, Romano E. Castelo-Branco L, et al. Among authors: pradervand s. ESMO Open. 2022 Jun;7(3):100499. doi: 10.1016/j.esmoop.2022.100499. Epub 2022 May 8. ESMO Open. 2022. PMID: 35644101 Free PMC article.
Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy.
Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco SA, Calderon-Copete S, Pais Ferreira D, Carmona SJ, Scarpellino L, Gfeller D, Pradervand S, Luther SA, Speiser DE, Held W. Siddiqui I, et al. Among authors: pradervand s. Immunity. 2019 Jan 15;50(1):195-211.e10. doi: 10.1016/j.immuni.2018.12.021. Epub 2019 Jan 8. Immunity. 2019. PMID: 30635237 Free article.
97 results